BVAXF
Biovaxys Technology Corp

516
Mkt Cap
$1.48M
Volume
12,499.00
52W High
$0.40
52W Low
$0.029
PE Ratio
-0.32
BVAXF Fundamentals
Price
$0.0509
Prev Close
$0.0508
Open
$0.0422
50D MA
$0.0993
Beta
-0.21
Avg. Volume
84,153.91
P/B
-0.56
Loading...
Loading...
News
all
press releases
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·4mo ago
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·4mo ago
News Placeholder
Phase 1 Results Drive New Attention to Breast Cancer Play
Immuno oncology remains one of the most closely watched areas in biotechnology, particularly as researchers search for ways to enhance standard therapies rather than replace them outright. Even early stage clinical data can move markets when it points to improved outcomes in large, underserved patient populations.Shares of BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) are trading higher Wednesday after the company reported positive Phase 1 clinical results for its investigational immunotherapy maveropepimut S, or MVP S, in women with hormone receptor positive, HER2 negative stage II ...
AllPennyStocks·4mo ago
<
...
1
>

Latest BVAXF News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.